Skip to main content

TNF inhibitor

    Rheumatology Roundup
    Drs. Jack Cush and Arthur Kavanaugh discuss highlights and key takeaways from ACR 23. This included the following abstracts: 0025 Cannibinoids & pain 1584 TMP/SMX in GPA 0607 CAR-T cells in…
    Impressive and important study supporting safety of TNF inhibitors among patients with RA-ILD. Elegant methods of target
    Impressive and important study supporting safety of TNF inhibitors among patients with RA-ILD. Elegant methods of target trial emulation. Congrats to the authors on plenary presentation! #ACR23 https://t.co/P7keAoOX7M
    We have known about the VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome for nearly 3 years, but prior to ACR Convergence 2023 there has been relatively little to say about…
    After 3 years, 25% (95% CI: 13 to 38) remained flare-free in the tapering TNFi group compared to 85% (70 to 93) in the s
    5 months ago
    After 3 years, 25% (95% CI: 13 to 38) remained flare-free in the tapering TNFi group compared to 85% (70 to 93) in the stable TNFi group, hazard ratio for flare of 9.4 (3.9 to 22.8), ARCTIC REWIND, Kjorholt K, LB Abst#L07 #ACR23 #ACRBest @RheumNow https://t.co/fqxfU3jE0q https://t.co/J0qBeKNsEW
    Treatments in SpA